Oorja Bio Initiated Phase 2 Trial for IPF Drug
The Houston-based firm has begun testing a new peptide therapeutic for idiopathic pulmonary fibrosis in a multicenter study.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do you believe new medical research is successfully improving outcomes for people with terminal illnesses?
Oorja Bio has initiated its ORBIT-IPF Phase 2 clinical trial, marking the first patient screening for its drug candidate ORJ-001. This randomized, double-blind, placebo-controlled study evaluates the safety and efficacy of the peptide in treating idiopathic pulmonary fibrosis.
Why it matters
Idiopathic pulmonary fibrosis remains a critical condition with a limited life expectancy of three to five years for the more than 150,000 affected U.S. adults. This trial aims to address the underlying epithelial damage associated with the disease.
The study tests ORJ-001, a peptide therapeutic designed to target alveolar epithelial type 2 cells, against a placebo. Participants in Part A will receive subcutaneous injections twice weekly over a 12-week duration.
The players
Oorja Bio
A Houston-based biotechnology company focused on developing peptide therapeutics and fibrosis treatments, backed by $34 million in Series A financing.
The details
ORJ-001 functions as a peptide therapeutic — a chain of amino acids designed to act like natural proteins — specifically targeting alveolar epithelial type 2 cells, which are critical for maintaining the lung's structural integrity. The trial employs an adaptive study design that monitors biomarkers of fibrosis and epithelial damage to assess the drug's mechanism. By focusing on these cells, the treatment seeks to halt the damage rather than merely managing symptoms.
Timeline
October 13, 2026: Oorja Bio announced the initiation of the ORBIT-IPF trial.
The Tech Race
This development marks a pivot in the fibrosis landscape toward regenerative-focused peptide therapies. It directly competes with existing treatment pipelines aiming to improve the current 3-to-5-year life expectancy for IPF patients.
The clinical trial is currently enrolling and screening patients, meaning access remains limited to trial participants at designated centers. The study's initial 12-week treatment window will determine whether the drug proceeds to broader clinical validation.
The takeaway
Oorja Bio is testing whether peptide-based targeting of alveolar cells can improve outcomes for idiopathic pulmonary fibrosis patients. The scientific community should monitor the forthcoming results of Part A of the ORBIT-IPF study to determine if the drug hits its safety and efficacy endpoints.
Further reading
For broader trends in drug development and regenerative medicine, visit the Biotech section.
More information
Track study updates and participant requirements on the clinical trial information portal.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe new medical research is successfully improving outcomes for people with terminal illnesses?
